Chemotherapy May Fuel Cancer Regrowth: New Research Reveals Disturbing Findings

The AHA! Team — Fri, 18 Jul 2025 05:27:38 +0000

Lori Alton via NaturalHealth365 – According to current statistics, about one million people a year (in the U.S. alone) undergo chemotherapy in an attempt to beat cancer. Yet this toxic treatment has a poor success rate in treating most kinds of cancer, and its benefits can be short-lived. Making the picture even grimmer is the fact that cancer recurrence after chemotherapy is frequently deadly. Now, from the front lines of cancer research comes the disturbing news that one particular type of chemotherapy can actually lead to cancer regrowth and recurrence. One approach to treating cancer creates a breeding ground for cancer stem cells Chemotherapy-induced senescence, often touted as a new weapon in cancer therapy, involves “putting cancer cells to sleep.” The protocol is intended to place cancer cells in a state of arrested growth, where they are alive but not dividing. While senescence is supposed to prevent further cancerous growth, new research shows that it can serve as a sort of “nursery” and safe harbor for cancer stem cells – the most dangerous and treatment-resistant type of cancer cells. A pair of recent studies reveal the consequences of therapy-induced senescence. In an explosive article published in Frontiers in Oncology, Markus Schosserer, Ph.D., wrote that there is ample evidence that senescent cancer cells can produce inflammatory molecules that promote a rich environment for cancer regrowth. In a breakthrough German study published in Nature, the team presented startling conclusions: senescence not only helps cancer cells avoid death but actually transforms them into cancer stem cells. This is very bad news, as stem cells – which can break from a tumor and metastasize throughout the body – are also the most resistant to treatment. Cancer cells can “outmaneuver” induced senescence In the German study, researchers examined human lymphoma cells treated with drugs to induce senescence and discovered they were developing “stemness.” In other words, the lymphoma cells started to express genes vital for maintaining stem cell function. When the team “released” the cancer cells from senescence, they discovered an alarming outcome. The cells began to multiply again – and more rapidly than those that had not become senescent. Although senescence is supposed to be irreversible, the team found evidence that cancer cells can escape it on their own – without the help of the genetic manipulation they used. Testament to this unfortunate possibility is that the scientists found more previously senescent stem cells in tumor patients after lymphoma recurred than had existed in the same individuals when they received their initial treatment. This demonstrated to the scientists that at least some cells had “figured out” how to outwit senescence. Noted professor of experimental oncology Dr. Jan Paul Medema commented, ‘There is compelling evidence … that … when cancer cells escape from senescence, they have an enhanced ability to drive tumor growth.’ Study leader Dr. Clemens A. Schmitt reported that switching off a specific cell signaling pathway could work to neutralize stemness in the previously senescent cells. However, there is no doubt that the study findings pose a definite setback for a formerly promising protocol. In addition, other studies have emerged showing that chemotherapy can do more harm than good. Chemotherapy for breast cancer can spread cancer cells A common protocol for breast cancer patients is to surgically remove tumors after chemo has been administered. The theory is that the chemo will help shrink the tumor while preventing the spread of cancer throughout the body. However, the treatment may accomplish the opposite effect. The toxic chemo drugs may actually switch on a repair mechanism – creating more blood vessel pathways and permitting tumors to grow back even stronger. In a study at the Albert Einstein College of Medicine, researchers found that chemotherapy triggered the circulation of more cancer cells throughout the lungs and the body. Chemotherapy features toxic side effects The American Cancer Society acknowledges that chemotherapy damages healthy cells – and reports that chemotherapy side effects include vomiting, diarrhea, anemia, hair loss, fertility problems, chronic fatigue, and infections. Neutropenia, the most serious side effect, involves the depletion of white blood cells needed to fight diseases and infections. Weight changes and mood changes – with depression, memory loss, and inability to concentrate – may also occur. Normal cells damaged by chemotherapy Normal cells most likely to be damaged by chemotherapy are cells in hair follicles, blood-forming cells in the bone marrow, cells in the mouth and digestive tract, and cells in the reproductive system. Experts report that in some situations – for example, the early stages of colorectal cancer – chemotherapy has been shown to provide some benefit, granting extra years of life. But on the whole, chemotherapy yields disappointing results and may even exacerbate cancer cell growth – as shown in this pair of startling studies. Editor’s note: Discover the many natural ways to stop cancer cell growth, own the Stop Cancer Docu-Class created by NaturalHealth365 Programs. Sources for this article include: NIH.gov Medicalnewstoday.com Sciencedaily.com Cancer.org To read the original article click here.

The post Chemotherapy May Fuel Cancer Regrowth: New Research Reveals Disturbing Findings appeared first on Amazing Health Advances.

Radio-Wave Therapy Is Safe for Liver Cancer Patients and Shows Improvement in Overall Survival

AHA Publisher — Mon, 02 Aug 2021 07:00:42 +0000

Wake Forest Baptist Medical Center via EurekAlert – Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. “HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months,” said Boris Pasche, M.D., Ph.D., chair of cancer biology and director of Wake Forest Baptist’s Comprehensive Cancer Center. “Currently, there are limited treatment options for patients with this advanced liver cancer.” For the study researchers used a device called TheraBionic P1, invented by Pasche and Alexandre Barbault of TheraBionic GmbH in Ettlingen, Germany, that works by delivering cancer-specific, amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) programmed specifically for HCC. The frequencies used are specific to the patient’s type of cancer as identified through tumor biopsies or blood work, Pasche said. Pasche and Barbault discovered radio frequencies for 15 different types of cancer, as previously reported in a study published in 2009 in the Journal of Experimental & Clinical Cancer Research. TheraBionic P1 is a hand-held device that emits radio frequencies via a spoon-shaped antenna, which is placed on the patient’s tongue during treatment and is administered three times a day for one hour to deliver low levels of radiofrequency electromagnetic fields throughout the patient’s body. In previous studies, the device, which received breakthrough designation from the FDA in 2019, was shown to block the growth of liver cancer cells in the body without damaging healthy cells. For the current study, 18 patients with advanced HCC participated and received treatment with the device. Researchers also analyzed previously published data on 41 patients from a phase II study and historical controls from earlier clinical trials. “Our findings show an improvement in overall survival of more than 30% in patients with well-preserved liver function and also in those with more severe disease,” Pasche said. Researchers also tracked side effects, and no patients stopped TheraBionic P1 treatment because of adverse reactions. “We’re encouraged by these initial findings,” Pasche said. “Our study shows a benefit in overall survival, and the treatment isn’t associated with any significant side effects.” Support for this study was provided by TheraBionic Inc. and funds from Wake Forest Baptist’s Comprehensive Cancer Center. Pasche noted that the study does have several limitations because of the small sample size and “selection bias inherent in the use of historical control data.” However, two additional clinical trials are underway and are being led by William Blackstock, M.D., chair of radiation oncology at Wake Forest Baptist’s Comprehensive Cancer Center. One is a single-center study to assess the safety and effectiveness of the TheraBionic device in combination with Regorafenib, a chemotherapy drug, as a second-line treatment. Another multicenter, double-blind, randomized study comparing TheraBionic with placebo will assess the safety and effectiveness of the device as a third-line therapy in the treatment of advanced HCC. To read the original article click here.

The post Radio-Wave Therapy Is Safe for Liver Cancer Patients and Shows Improvement in Overall Survival appeared first on Amazing Health Advances.

chemotherapy drug Archives - Amazing Health Advances

Chemotherapy May Fuel Cancer Regrowth: New Research Reveals Disturbing Findings

Radio-Wave Therapy Is Safe for Liver Cancer Patients and Shows Improvement in Overall Survival